Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $10.88 and traded as low as $9.95. Coloplast A/S shares last traded at $9.95, with a volume of 203,967 shares traded.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on CLPBY. Royal Bank of Canada upgraded shares of Coloplast A/S from a “hold” rating to a “moderate buy” rating in a research report on Monday, March 3rd. Sanford C. Bernstein raised shares of Coloplast A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 28th. Finally, UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a report on Wednesday, December 11th.
View Our Latest Stock Analysis on Coloplast A/S
Coloplast A/S Stock Performance
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.01). Coloplast A/S had a return on equity of 28.60% and a net margin of 17.81%. Research analysts anticipate that Coloplast A/S will post 0.31 EPS for the current fiscal year.
About Coloplast A/S
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.
Featured Stories
- Five stocks we like better than Coloplast A/S
- Pros And Cons Of Monthly Dividend Stocks
- Newsmax’s IPO Whiplash: Meme Stock Hype or Growth Potential?
- What Does Downgrade Mean in Investing?
- Disney 2025 Shareholders: Major Updates for Investors
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Advance Auto Parts Stock: A Classic Rebound Play in the Making
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.